CompletedNot Applicable

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

United States50 participantsStarted 2013-10

Plain-language summary

To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another. To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All individuals age 18yrs and above capable of rendering consent * Known ITP confirmed by response to intravenous immune globulin (IVIG), glucocorticoids, or winRho and exclusion of all other possible causes of thrombocytopenia * Confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\] * Chemotherapy induced thrombocytopenia assessed at time of predicted nadir. Exclusion Criteria: * Suspected multifactorial thrombocytopenias and thrombocytopenia due to hypersplenism * Chronic active hepatitis * Those infected with HIV * Patients receiving concomitant radiotherapy * Gravid females * Congenital thrombocytopenias

What they're measuring

Increased platelet density

Timeframe: 12 months

Trial details

NCT IDNCT01933035

SponsorBeth Israel Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2015-10

View on ClinicalTrials.gov More Immune Thrombocytopenia trials